Oncogene-mediated regulation of p53 ISGylation and functions

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5808-5818

  Huang, Yi Fu ^a   Bulavin, Dmitry V ^a,b  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

Author keywords

Cancer; ISG15; p53; Protein degradation

Indexed keywords

HERC5 PROTEIN; INTERFERON STIMULATED GENE 15; K RAS PROTEIN; MYC PROTEIN; NUTLIN 3; PROTEIN P53; PROTEIN TYROSINE KINASE; RAS PROTEIN; TRANSCRIPTION FACTOR; TYROSINE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CYTOKINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOPLASM; DNA DAMAGE; EMBRYO; GENE DELETION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG SQUAMOUS CELL CARCINOMA; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TUMOR GROWTH; UPREGULATION; ANIMAL; GENETICS; HCT116 CELL LINE; HEK293 CELL LINE; MCF 7 CELL LINE; METABOLISM; PHOSPHORYLATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; HCT116 CELLS; HEK293 CELLS; HUMANS; MCF-7 CELLS; MICE; ONCOGENES; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINS;

EID: 84906256771     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2199     Document Type: Article

References (26)

1. Huang YF, Wee S, Gunaratne J, Lane DP and Bulavin DV. Isg15 controls p53 stability and functions. Cell Cycle. 2014; 13(14). [Epub ahead of print]
2. Korant BD, Blomstrom DC, Jonak GJ and Knight E Jr. Interferon-induced proteins. Purification and characterization of a 15,000-dalton protein from human and bovine cells induced by interferon. J Biol Chem. 1984; 259 (23):14835-14839.
3. Kim MJ, Latham AG, and Krug RM. Human influenza viruses activate an interferon-independent transcription of cellular antiviral genes: outcome with influenza A virus is unique. Proc Natl Acad Sci U S A. 2002; 99 (15):10096-10101.
4. Loeb KR, and Haas AL. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J Biol Chem. 1992; 267 (11):7806-7813.
5. Malakhova O, Malakhov M, Hetherington C, and Zhang DE. Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. J Biol Chem. 2002; 277 (12):14703-14711.
6. Yang P, Yu Z, Gandahi JA, Bian X, Wu L, Liu Y, Zhang L, Zhang Q and Chen Q. The identification of c-Kit-positive cells in the intestine of chicken. Poult Sci. 2012; 91(9):2264-2269.
7. Kim KI, Giannakopoulos NV, Virgin HW and Zhang DE. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol Cell Biol. 2004; 24 (21):9592-9600.
8. Wong JJ, Pung YF, Sze NS and Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci U S A, 2006; 103 (28):10735-10740.
9. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, Huibregtse JM, and Krug RM. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc Natl Acad Sci U S A, 2004; 101 (20):7578-7582.
10. Zou W and Zhang DE. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem.2006; 281 (17):3989-3994.
11. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, Saleem A, Nur EKA and Liu LF. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res.2006; 66(2): 921-928.
12. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol.2003; 162 (4):1151-1162.
13. Bektas N, Noetzel E, Veeck J, Press MF, Kristiansen G, Naami A, Hartmann A, Dimmler A, Beckmann MW, Knuchel R et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res. 2008; 10(4):R58.
14. Desai SD, Reed RE, Burks J, Wood LM, Pullikuth AK, Haas AL, Liu LF, Breslin JW, Meiners S and Sankar S. ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells. Exp Biol Med (Maywood). 2012; 237(1):38-49.
15. Andersen JB, Aaboe M, Borden EC, Goloubeva OG, Hassel BA and Orntoft TF. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer.2006; 94(10):1465-1471.
16. Kiessling A, Hogrefe C, Erb S, Bobach C, Fuessel S, Wessjohann L and Seliger B. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene. 2009; 28(28):2606-2620.
17. Satake H, Tamura K, Furihata M, Anchi T, Sakoda H, Kawada C, Iiyama T, Ashida S and Shuin T. The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer. Oncol Rep.2010; 23(1):11-16.
18. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2(5):401-404.
19. Shieh SY, Ikeda M, Taya Y and Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell.1997; 91(3):325-334.
20. Joseph TW, Zaika A and Moll UM. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. FASEB J; 2003; 17(12):1622-1630.
21. Qiao Y, Molina H, Pandey A, Zhang J and Cole PA. Chemical rescue of a mutant enzyme in living cells. Science.2006; 311 (5765):1293-1297.
22. Milner J, Cook A and Sheldon M. A new anti-p53 monoclonal antibody, previously reported to be directed against the large T antigen of simian virus 40. Oncogene. 1987; 1(4): 453-455.
23. Gannon JV, Greaves R, Iggo R and Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J, 1990; 9(5):1595-1602.
24. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA and Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001; 410 (6832):1111-1116.
25. Janas JA and Van Aelst L. Oncogenic tyrosine kinases target Dok-1 for ubiquitin-mediated proteasomal degradation to promote cell transformation. Mol Cell Biol. 2011; 31(13):2552-2565.
26. Le Guezennec X, Brichkina A, Huang YF, Kostromina E, Han W and Bulavin DV. Wip1-dependent regulation of autophagy, obesity, and atherosclerosis. Cell Metab. 2012; 16(1):68-80.